---

Safety and efficacy of Tiotropium bromide compared with placebo in COPD and Bronchial Asthma

---

Original Article

Author Details : Ahmed Abdul Bari Hazari*

Volume : 6, Issue : 4, Year : 2019

Article Page : 145-148

https://doi.org/10.18231/j.ijpp.2019.031

Suggest article by email

Get Permission

---

Abstract

Introduction: Tiotropium is well tolerated, with a safety profile comparable with that of placebo.
Objective: To know the safety and efficacy of Tiotropium bromide compared with placebo.
Material and Methods: The present clinical study was conducted in patients with stable as well as exacerbated COPD and Br. Asthma at Shadan Hospital, Telengana State from May 2015 to Feb 2016.
Results: In case of Br. Asthma patient (n-10), the FEV_­1 improved to 0.18 L (26.16%) with respect to baseline 0.15 L (P value < 0>1/FVC ratio is improved by 65.10% (5.51%) with respect to the baseline 61.70% (P<0>th weeks of period. In case of COPD patients the FEV₁ is improved by 0.17 L (23.64%) with respect to baseline 0.14 L (P value < 0>1/FVC value improved by 64.72% (7.11%) with respect to the baseline 60.42% (P value < 0>
Conclusion: In spirometric as well as clinically, placebo in COPD group patients (n-7) and Br. Asthma group patients (n-10) showed very less improvement, which is statistically not significant.

Keywords: Bronchial Asthama, COPD, Placebo, FEV_­1, FEV₁/FVC, FVC.

How to cite : Hazari A A B, Safety and efficacy of Tiotropium bromide compared with placebo in COPD and Bronchial Asthma. Indian J Pharm Pharmacol 2019;6(4):145-148

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.